Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness and to promote further cooperation between the University of Oxford and Diamond Light Source, the UK’s national synchrotron has been agreed upon.

The University and Diamond Light Source already have many strong links but now intend to develop their collaborative work to address multiple aspects of anti-viral drug discovery in particular structure-based drug discovery, development of immuno-therapeutics and vaccine design.

Richard Cornall, Nuffield Professor of Clinical Medicine and Head of Department of the Nuffield Department of Medicine (NDM) at the University of Oxford said: “Over the years we have had many research collaborations with Diamond including its Electron Bio-Imaging Centre (eBIC). This has been reinforced by a number of high-level joint appointments and secondments of principal investigators between Diamond and NDM.  This agreement recognises that our strengths continue to be highly complementary and that by working together we will have the best chance of developing life-saving ways to prevent and treat our most significant pandemic threats.”

Prof Sir Dave Stuart, MRC Professor of Structural Biology at NDM, Head of the Division of Structural Biology and the Director of Life Sciences at Diamond Light Source adds: “This new agreement will enable us to identify collaborative research opportunities for joint research, development both of mutual or individual interest and to coherently address multiple aspects of therapy development form anti-viral drug discovery to vaccine design.”

The University and Diamond Light Source intend to develop their collaborative work in the following project areas:

  • Structure-based drug discovery and development of immuno-therapeutics. Both facilities will look for ways to bring their assets and partnerships to bear on a joint cross-disciplinary platform to develop novel class-specific anti-viral drugs and immune-therapeutics. One major shared goal is rapid generation of small molecule and protein hits, refinement to potent leads and in vitro assessment. They may also identify ways to use their shared resources to create a pipeline comprising structure-based drug discovery, in vitro and in vivo assay development, innovative and automated approaches to drug design, advanced enzymology/protein science synthesis and development.
  • A second shared aim is focused on structural characterisation of the mode of action of neutralising antibodies or nanobodies and the use of such information in the development of new immuno-therapeutic entities.
  • Vaccine design. The facilities will look to identify ways to bring their assets and partnerships to bear on the generation of high-resolution structural data, and appropriate cellular imaging data, to feed into the design of novel vaccines and the refinement and optimisation of vaccination strategies.

 

In 2021, The University established the Pandemic Sciences Institute, hosted by NDM, as a multi-disciplinary, university-wide initiative to build upon the model of innovation, collaboration and agility that yielded critical breakthroughs for COVID-19, and to identify and counter future pandemic threats. 

Diamond Light Source, the UK’s national synchrotron, co-founded the COVID Moonshot, a spontaneous global collaboration that started in March 2020, triggered by data from Diamond’s XChem platform for fragment screening, and rapidly identified potent antivirals targeting the main protease of the SARS-CoV-2 virus. These antivirals are now undergoing a preclinical programme funded by the Wellcome Trust, and data openly shared by Moonshot additionally enabled the identification of another promising COVID-19 drug developed by the Japanese pharmaceutical company Shionogi that is now in late-stage clinical trials.

Similar stories

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

NDM student Romain Guyon awarded the 2022 Michelson Prize

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Essential research by COI improves understanding of COVID

Since the start of the pandemic, the CAMS-Oxford Institute (COI) has carried out 11 projects to better understand COVID-19, resulting in 21 published research articles.

Sarah Gilbert awarded 2023 King Faisal Prize

Professor Dame Sarah Gilbert, the Saïd Chair of Vaccinology in the Nuffield Department of Medicine has been selected to receive King Faisal Prize for Medicine for 2023, along with Professor Dan Barouch of Harvard Medical School.

Three NDM researchers awarded Associate Professorships

We are delighted to announce that three researchers have been awarded the Associate Professor title, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.

Oxford Ebola vaccine manufactured and shipped in record time

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by Serum Institute of India (SII) in just 60 days and doses shipped to Uganda.